Finance

Beta
Lists
SLNCF:OTCMKTS
Silence Therapeutics plc
$1.06
0.00%
(0.00) 1D
May 20, 3:59:07 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SLNCF...
Mkt. cap
291.44M
Avg. vol.
151.00
Volume
0.00
52-wk high
$2.63
52-wk low
$1.06
EPS
-$0.53
Beta
1.38
Shares outstanding
141.70M
No. of employees
88
Mkt. cap
291.44M
Avg. vol.
151.00
Volume
0.00
52-wk high
$2.63
52-wk low
$1.06
EPS
-$0.53
Beta
1.38
Shares outstanding
141.70M
No. of employees
88
News stories
From sources across the web
Profile
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London. Wikipedia
About Silence Therapeutics plc
CEOCraig A Tooman
Employees88
Founded1994
Headquarters-
SectorBiotechnology
Websitesilence-therapeutics.com
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
224.00K
159.00K
34.00K
422.00K
Cost of goods sold
85.00K
64.00K
12.00K
11.00K
Cost of revenue
85.00K
64.00K
12.00K
11.00K
Research and development expenses
15.28M
17.96M
8.92M
8.43M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.13M
5.80M
3.73M
7.03M
Operating expense
20.41M
23.76M
12.65M
15.46M
Total operating expenses
20.49M
23.82M
12.66M
15.47M
Operating income
-20.27M
-23.66M
-12.63M
-15.05M
Other non operating income
861.00K
770.00K
865.00K
571.00K
EBT including unusual items
-27.34M
-20.96M
-11.77M
-14.96M
EBT excluding unusual items
-26.02M
-20.96M
-11.77M
-14.96M
Income tax expense
10.00K
1.00K
-
-
Effective tax rate
-0.04%
-
-
-
Other operating expenses
-
-
-
-
Net income
-27.35M
-20.96M
-11.77M
-14.96M
Net profit margin
-12,211.61%
-13,181.13%
-34,617.65%
-3,544.31%
Earnings per share
-0.55
-0.15
-0.27
-0.33
Interest and investment income
-
-
15.00K
-
Interest expense
-
-
-
-
Net interest expenses
-
-
15.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.12M
-23.50M
-12.52M
-14.94M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer